New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis
Clinical Science · 18.05.2023 · 137 (9) · 727-753
DOI: 10.1042/cs20190281 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, online erschienen am 18.05.2023. Verfasst von Ilja Striz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Hauptthemen laut MEDLINE: Nasal Polyps, Asthma, Sinusitis, Rhinitis. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 292 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) or without (CRSsNP) are chronic respiratory diseases. These two disorders often co-exist based on common anatomical, immunological, histopathological, and pathophysiological basis. Usually, asthma with comorbid CRSwNP is driven by type 2 (T2) inflammation which predisposes to more severe, often intractable, disease. In the past two decades, innovative technologies and detection techniques in combination with newly introduced targeted therapies helped shape our understanding of the immunological pathways underlying inflammatory airway diseases and to further identify several distinct clinical and inflammatory subsets to enhance the development of more effective personalized treatments. Presently, a number of targeted biologics has shown clinical efficacy in patients with refractory T2 airway inflammation, including anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab)/anti-IL5R (benralizumab), anti-IL-4R-α (anti-IL-4/IL-13, dupilumab), and anti-TSLP (tezepelumab). In non-type-2 endotypes, no targeted biologics have consistently shown clinical efficacy so far. Presently, multiple therapeutical targets are being explored including cytokines, membrane molecules and intracellular signalling pathways to further expand current treatment options for severe asthma with and without comorbid CRSwNP. In this review, we discuss existing biologics, those under development and share some views on new horizons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- Subdivision of Allergology and Clinical Immunology, Institute for Postgraduate Education in Medicine, Prague, Czech Republic.
- Department of Pulmonary Medicine, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
- Institute of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
- Department of Respiratory Medicine, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Ilja Striz, Zuzana Diamant
Zitieren
APA
Striz, I., Golebski, K., Strizova, Z., Loukides, S., Bakakos, P., Hanania, N. A., Jesenak, M., & Diamant, Z. (2023). New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clinical Science, 137(9), 727-753. https://doi.org/10.1042/cs20190281
Vancouver
Striz I, Golebski K, Strizova Z, Loukides S, Bakakos P, Hanania NA, et al. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis. Clinical Science. 2023;137(9):727-753. doi:10.1042/cs20190281
BibTeX
@article{Striz2023,
author = {Striz, Ilja and Golebski, Kornel and Strizova, Zuzana and Loukides, Stelios and Bakakos, Petros and Hanania, Nicola A and Jesenak, Milos and Diamant, Zuzana},
title = {New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis},
journal = {Clinical Science},
year = {2023},
volume = {137},
number = {9},
pages = {727--753},
doi = {10.1042/cs20190281}
}
EUVIMED